These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11890191)

  • 1. High-dose olanzapine in Huntington's disease.
    Bonelli RM; Niederwieser G; Tribl GG; Költringer P
    Int Clin Psychopharmacol; 2002 Mar; 17(2):91-3. PubMed ID: 11890191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine for Huntington's disease: an open label study.
    Bonelli RM; Mahnert FA; Niederwieser G
    Clin Neuropharmacol; 2002; 25(5):263-5. PubMed ID: 12410058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine in Huntington's disease.
    Paleacu D; Anca M; Giladi N
    Acta Neurol Scand; 2002 Jun; 105(6):441-4. PubMed ID: 12027832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine and Huntington's disease.
    Bogelman G; Hirschmann S; Modai I
    J Clin Psychopharmacol; 2001 Apr; 21(2):245-6. PubMed ID: 11270928
    [No Abstract]   [Full Text] [Related]  

  • 5. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.
    Etchebehere EC; Lima MC; Passos W; Maciel Júnior JA; Santos AO; Ramos CD; Camargo EE
    Arq Neuropsiquiatr; 1999 Sep; 57(3B):863-6. PubMed ID: 10751925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Olanzapine improves chorea in patients with Huntington's disease].
    Jiménez-Jiménez FJ; de Toledo M; Puertas I; Barón M; Zurdo M; Barcenilla B
    Rev Neurol; 2002 Sep 16-30; 35(6):524-5. PubMed ID: 12389168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and motor response to low dose olanzapine in Huntington's disease: case report.
    Laks J; Rocha M; Capitão C; Domingues RC; Ladeia G; Lima M; Engelhardt E
    Arq Neuropsiquiatr; 2004 Dec; 62(4):1092-4. PubMed ID: 15608976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riluzole and olanzapine in Huntington's disease.
    Bonelli RM; Niederwieser G; Diez J; Költringer P
    Eur J Neurol; 2002 Mar; 9(2):183-4. PubMed ID: 11882065
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of olanzapine for movement disorder in Huntington's disease: a first case report.
    Dipple HC
    J Neurol Neurosurg Psychiatry; 1999 Jul; 67(1):123-4. PubMed ID: 10454874
    [No Abstract]   [Full Text] [Related]  

  • 10. Zotepine in Huntington's disease.
    Bonelli RM; Niederwieser G; Lahousen T; Hofmann P
    Hum Psychopharmacol; 2003 Apr; 18(3):227-9. PubMed ID: 12672176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of Huntington's disease with olanzapine and valproate.
    Grove VE; Quintanilla J; DeVaney GT
    N Engl J Med; 2000 Sep; 343(13):973-4. PubMed ID: 11012330
    [No Abstract]   [Full Text] [Related]  

  • 12. Apraxia of eyelid closure in Huntington's disease.
    Bonelli RM; Niederwieser G
    J Neural Transm (Vienna); 2002 Feb; 109(2):197-201. PubMed ID: 12075860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of olanzapine in Huntington disease.
    Squitieri F; Cannella M; Porcellini A; Brusa L; Simonelli M; Ruggieri S
    Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):69-72. PubMed ID: 11234911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.
    Coppen EM; Roos RA
    Drugs; 2017 Jan; 77(1):29-46. PubMed ID: 27988871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
    Wright P; Meehan K; Birkett M; Lindborg SR; Taylor CC; Morris P; Breier A
    Clin Ther; 2003 May; 25(5):1420-8. PubMed ID: 12867218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.
    Olson DA; Ingram W; Mann JR
    J Clin Psychopharmacol; 2002 Oct; 22(5):529-30. PubMed ID: 12352281
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid onset of tardive dyskinesia in Huntington disease with olanzapine.
    Benazzi F
    J Clin Psychopharmacol; 2002 Aug; 22(4):438-9. PubMed ID: 12172349
    [No Abstract]   [Full Text] [Related]  

  • 19. The efficacy of olanzapine, as needed, to treat acute agitation in juveniles.
    Sheikh RM; Ahmed K
    J Child Adolesc Psychopharmacol; 2002; 12(1):71-3. PubMed ID: 12014599
    [No Abstract]   [Full Text] [Related]  

  • 20. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.